6/4
08:09 am
cue
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting [Yahoo! Finance]
Medium
Report
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting [Yahoo! Finance]
6/4
08:00 am
cue
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Medium
Report
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
6/3
08:08 am
cue
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024 [Yahoo! Finance]
Medium
Report
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024 [Yahoo! Finance]
6/3
08:00 am
cue
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
Medium
Report
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
5/9
04:24 pm
cue
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
5/9
04:05 pm
cue
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
Medium
Report
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
5/8
08:21 am
cue
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit [Yahoo! Finance]
Medium
Report
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit [Yahoo! Finance]
5/8
08:00 am
cue
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
Medium
Report
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
5/7
08:00 am
cue
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
Medium
Report
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
4/25
11:44 am
cue
Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks [Yahoo! Finance]
Medium
Report
Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks [Yahoo! Finance]
4/24
10:15 am
cue
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Medium
Report
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
4/24
10:01 am
cue
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Medium
Report
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
4/15
12:10 pm
cue
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]
Medium
Report
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]
4/9
09:08 am
cue
Cue Biopharma, Inc. (NASDAQ: CUE) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $8.00 price target on the stock.
Medium
Report
Cue Biopharma, Inc. (NASDAQ: CUE) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $8.00 price target on the stock.
4/9
08:44 am
cue
Cue Biopharma, Inc. (NASDAQ: CUE) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.
Low
Report
Cue Biopharma, Inc. (NASDAQ: CUE) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.
4/8
04:11 pm
cue
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights [Yahoo! Finance]
Medium
Report
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights [Yahoo! Finance]
4/8
04:05 pm
cue
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
Medium
Report
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
4/3
12:11 pm
cue
Cue Biopharma, Inc. (NASDAQ: CUE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $8.00 price target on the stock.
Low
Report
Cue Biopharma, Inc. (NASDAQ: CUE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $8.00 price target on the stock.
4/2
08:24 am
cue
Cue Biopharma to Host Business Update Call and Webcast [Yahoo! Finance]
Medium
Report
Cue Biopharma to Host Business Update Call and Webcast [Yahoo! Finance]
4/2
08:00 am
cue
Cue Biopharma to Host Business Update Call and Webcast
Medium
Report
Cue Biopharma to Host Business Update Call and Webcast